Impact of Breathing Route on CPAP Effectiveness to Treat Obstructive Sleep Apnea

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05272761
Collaborator
(none)
20
1
37.3
0.5

Study Details

Study Description

Brief Summary

To determine the impact of the CPAP route (oronasal vs oral) in patients diagnosed with moderate-severe OSA using CPAP with oronasal mask on CPAP level, residual AHI, and peak flow. In addition, the impact of position (lateral vs supine position) will be evaluated during PSG.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Application of Continuous Positive Upper Airway Pressure (CPAP) during sleep using nasal mask is the gold standard treatment for Obstructive Sleep Apnea (OSA). In clinical practice, many patients with OSA are considered mouth breathers and use an oronasal mask. However, CPAP delivered by the mouth violates the principal of CPAP use to treat OSA. This study is part of a line of research over the last decade that started with the observation of a patient that CPAP delivered by an oronasal mask failed to splint the airway open and to abolish OSA . We showed subsequently in acute studies during induced-sleep that oronasal CPAP only works when the patient breathes predominantly through the nose. These observations prompted our group to lead one workshop on the importance of mask selection. One meta-analysis from our group confirmed that oronasal CPAP is associated with a higher CPAP level, higher residual AHI, and poorer adherence than nasal CPAP. Despite all this evidence the investigators intrigued by the clinical observation that oronasal masks remains common and several patients on clinical practice are well adapted to oronasal CPAP. In this study, 20 patients with OSA well adapted to the oronasal mask will be recruited. The patients will be invited to be submitted to 2 independent CPAP titration sleep studies using a customized oronasal mask with a sealed and independent nasal and oral compartments coupled to 2 pneumotachographs. One CPAP titration will be with the nasal and oral routes open and one CPAP titration with only the oral compartment opened. Our hypotheses are that obstruction of nasal compartment during CPAP titration causuing mouth breathing will result in higher CPAP and higher residual apnea-hypopnea index. Patients with OSA under treatment with oronasal CPAP will undergo CPAP titration polysomnography on 2 different nights. In one night the patient will sleep with the oral and nasal compartments opened and in another night interposed by at least seven days, the patient with sleep with only the oral compartment opened. The order of the 2 sleep studies will be randomized. Thus, researchers will assess the impact of the airway (oral vs oronasal) on titrated CPAP level, residual AHI, and sleep efficiency in supine and lateral recumbency. In addition, the preferred airway during the oronasal mask will be analyzed. At the end of the study a nasal mask will be offered to all patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Impact of Breathing Route on the Effectiveness of Treatment of Obstructive Sleep Apnea With CPAP and Oronasal Mask
    Actual Study Start Date :
    Jan 10, 2021
    Anticipated Primary Completion Date :
    Jul 1, 2022
    Anticipated Study Completion Date :
    Feb 18, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Oronasal Route

    Patients will sleep in the sleep lab for CPAP titration wearing a custom oronasal mask with 2 open oral and nasal compartments. The titration was split between the first half of the night and the second half. The titration will be started with the patient remaining for 90 minutes with the pressure he uses at home (supine position and in lateral decubitus), after a period of 90 minutes the patient will be titrated in order to abolish respiratory events in both positions of the body.

    Oral Route

    Group/Cohort Interventions Oronasal Route Patients will sleep in the sleep lab for CPAP titration using a custom 2-compartment oronasal mask. In this titration, the nasal compartment will be closed and the patient will be titrated only through the oral route. The titration split between the first half of the night and the second half. The titration will be started with the patient staying for 90 minutes with the pressure used at home (during the supine position and lateral position), after the 90 minute period the patient will be titrated in order to abolish respiratory events in both positions of the body.

    Outcome Measures

    Primary Outcome Measures

    1. Impact of breathing route on residual AHI [2 nights]

      To determine the impact of the CPAP route (oronasal vs oral) in patients diagnosed with moderate-severe OSA using oronasal mask on residual AHI ( Apnea-hypopnea Index).

    2. Impact of breathing route on the CPAP [2 nights]

      To determine the impact of the CPAP route (oronasal vs oral) in patients during titration of the CPAP route (oronasal vs oral)

    Secondary Outcome Measures

    1. Influence of position [2 nights]

      To assess the influence of body position on the CPAP pressure used at home by the patient in the oral and oronasal route.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of moderate or severe OSA in treatment with CPAP in an oronasal mask

    • 18 Years to 85 Years (Adult, Older Adult) (Adult, Older Adult)

    Exclusion Criteria:
    • Other sleep disturbance (insomnia, parasomnias, narcolepsy, central sleep apnea).

    • Uncontrolled clinical disease (diabetes, kidney or heart failure, recent stroke or coronary failure and recent postoperative period, oxygen dependent COPD).

    • Patients adapted to other types of masks.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fundação Zerbini - Instituto do Coração (InCor) São Paulo SP Brazil 054039000

    Sponsors and Collaborators

    • University of Sao Paulo General Hospital

    Investigators

    • Principal Investigator: Geraldo Lorenzi-Filho, PHD, Hospital das Clínicas HCFMUSP

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Geraldo Lorenzi Filho, Principal Investigator, University of Sao Paulo General Hospital
    ClinicalTrials.gov Identifier:
    NCT05272761
    Other Study ID Numbers:
    • 4901/19/120
    First Posted:
    Mar 9, 2022
    Last Update Posted:
    May 3, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Geraldo Lorenzi Filho, Principal Investigator, University of Sao Paulo General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 3, 2022